Geneious Prime Enterprise Licenses

The Centers for Disease Control and Prevention (CDC) Office of Acquisition Services is soliciting offers for 200 fixed-seat licenses of Geneious Prime Enterprise software through a Request for Quote (RFQ) to support bioinformatics and DNA sequence analysis for pathogen surveillance and outbreak response. This procurement is brand-name specific, and equivalent products will not be accepted. Proposals will be evaluated based on three factors in descending order of importance: Technical Approach and Capability, Price, and Past Performance, with the government evaluating total pricing for both the base period and optional year combined. All proposals must address Section 508 accessibility compliance and submit an Accessibility Conformance Report, along with comprehensive security, privacy, and IT requirements including employee training, encryption standards, and incident response procedures. Questions regarding the solicitation are due by January 22, 2026, at 5:00 PM Eastern Time, and completed proposals must be submitted by February 2, 2026, at 11:00 AM Eastern Time. The Contracting Officer is H. Taylor Wellman (xur0@cdc.gov, 404-498-6020).

This procurement is designated as a total small business set-aside. The contract represents a replacement of the CDC's current arrangement of 40 floating licenses with fixed-seat licenses providing approximately equivalent capacity. The base contract period runs from February 23, 2026, through February 22, 2027, with one optional 12-month extension extending through February 22, 2028. While a specific budget or award value is not disclosed in the solicitation notice, the contract covers 200 fixed-seat licenses for a 24-month period including the optional extension. Place of performance is Atlanta, Georgia, and the solicitation is categorized under Software Publishers (NAICS 513210) and IT and Telecom Business Application Software (PSC 7A21).